Spark Therapeutics, Inc. drugs

1 result
  • luxturna

    (voretigene neparvovec-rzyl)
    Spark Therapeutics, Inc.
    LUXTURNA (voretigene neparvovec-rzyl) is indicated for treating patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy, provided they have viable retinal cells as determined by their physician.